SrasV1, PascalFrancis, Curation, bibRecord, 000538

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

Identifieur interne : 000538 ( PascalFrancis/Curation ); précédent : 000537; suivant : 000539

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

Auteurs : Jan Balzarini [Belgique] ; Els Keyaerts [Belgique] ; Leen Vijgen [Belgique] ; Herman Egberink [Pays-Bas] ; Erik De Clercq [Belgique] ; Marc Van Ranst [Belgique] ; Svetlana S. Printsevskaya [Russie] ; Eugenia N. Olsufyeva [Russie] ; Svetlana E. Solovieva [Russie] ; Maria N. Preobrazhenskaya [Russie]

Source :

Antiviral research [ 0166-3542 ] ; 2006.

RBID : Pascal:06-0491667

Descripteurs français

Pascal (Inist)
- Homme, Virus syndrome respiratoire aigu sévère, Glycopeptide, Antibiotique, Antiviral, Relation structure activité, Syndrome respiratoire aigu sévère, Vancomycine, Teïcoplanine, Virus péritonite infectieuse féline, Recherche développement, Eremomycine.
Wicri :
- topic : Homme, Antibiotique.

English descriptors

KwdEn :
- Antibiotic, Antiviral, Feline infectious peritonitis virus, Glycopeptide, Human, Research and development, Severe acute respiratory syndrome, Severe acute respiratory syndrome virus, Structure activity relation, Teicoplanin, Vancomycin.

Abstract

Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC₅₀) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC₅₀ values of the glycopeptide derivatives for FIPV or SARS-CoV.

A01	`01`	`1`		`@0 0166-3542`
A02	`01`			`@0 ARSRDR`
A03		`1`		`@0 Antivir. res.`
A05				`@2 72`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics`
A11	`01`	`1`		`@1 BALZARINI (Jan)`
A11	`02`	`1`		`@1 KEYAERTS (Els)`
A11	`03`	`1`		`@1 VIJGEN (Leen)`
A11	`04`	`1`		`@1 EGBERINK (Herman)`
A11	`05`	`1`		`@1 DE CLERCQ (Erik)`
A11	`06`	`1`		`@1 VAN RANST (Marc)`
A11	`07`	`1`		`@1 PRINTSEVSKAYA (Svetlana S.)`
A11	`08`	`1`		`@1 OLSUFYEVA (Eugenia N.)`
A11	`09`	`1`		`@1 SOLOVIEVA (Svetlana E.)`
A11	`10`	`1`		`@1 PREOBRAZHENSKAYA (Maria N.)`
A14	`01`			`@1 Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10 @2 3000 Leuven @3 BEL @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut.`
A14	`02`			`@1 Institute of Virology, Faculty of Veterinary Medicine, University of Utrecht @2 Utrecht @3 NLD @Z 4 aut.`
A14	`03`			`@1 Gause Institute of New Antibiotics, Russian Academy of Medical Sciences @2 Moscow @3 RUS @Z 7 aut. @Z 8 aut. @Z 9 aut. @Z 10 aut.`
A20				`@1 20-33`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 18839 @5 354000142223690030`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.1/2`
A47	`01`	`1`		`@0 06-0491667`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Antiviral research`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC₅₀) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC₅₀ values of the glycopeptide derivatives for FIPV or SARS-CoV.
C02	`01`	`X`		`@0 002B02S05`
C03	`01`	`X`	`FRE`	`@0 Homme @5 01`
C03	`01`	`X`	`ENG`	`@0 Human @5 01`
C03	`01`	`X`	`SPA`	`@0 Hombre @5 01`
C03	`02`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @2 NW @5 02`
C03	`02`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @2 NW @5 02`
C03	`02`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @2 NW @5 02`
C03	`03`	`X`	`FRE`	`@0 Glycopeptide @5 03`
C03	`03`	`X`	`ENG`	`@0 Glycopeptide @5 03`
C03	`03`	`X`	`SPA`	`@0 Glicopéptido @5 03`
C03	`04`	`X`	`FRE`	`@0 Antibiotique @5 04`
C03	`04`	`X`	`ENG`	`@0 Antibiotic @5 04`
C03	`04`	`X`	`SPA`	`@0 Antibiótico @5 04`
C03	`05`	`X`	`FRE`	`@0 Antiviral @5 05`
C03	`05`	`X`	`ENG`	`@0 Antiviral @5 05`
C03	`05`	`X`	`SPA`	`@0 Antiviral @5 05`
C03	`06`	`X`	`FRE`	`@0 Relation structure activité @5 06`
C03	`06`	`X`	`ENG`	`@0 Structure activity relation @5 06`
C03	`06`	`X`	`SPA`	`@0 Relación estructura actividad @5 06`
C03	`07`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 07`
C03	`07`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 07`
C03	`07`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 07`
C03	`08`	`X`	`FRE`	`@0 Vancomycine @2 NK @2 FR @5 08`
C03	`08`	`X`	`ENG`	`@0 Vancomycin @2 NK @2 FR @5 08`
C03	`08`	`X`	`SPA`	`@0 Vancomicina @2 NK @2 FR @5 08`
C03	`09`	`X`	`FRE`	`@0 Teïcoplanine @2 NK @2 FR @5 09`
C03	`09`	`X`	`ENG`	`@0 Teicoplanin @2 NK @2 FR @5 09`
C03	`09`	`X`	`SPA`	`@0 Teicoplanina @2 NK @2 FR @5 09`
C03	`10`	`X`	`FRE`	`@0 Virus péritonite infectieuse féline @2 NW @5 10`
C03	`10`	`X`	`ENG`	`@0 Feline infectious peritonitis virus @2 NW @5 10`
C03	`10`	`X`	`SPA`	`@0 Feline infectious peritonitis virus @2 NW @5 10`
C03	`11`	`X`	`FRE`	`@0 Recherche développement @5 11`
C03	`11`	`X`	`ENG`	`@0 Research and development @5 11`
C03	`11`	`X`	`SPA`	`@0 Investigación desarrollo @5 11`
C03	`12`	`X`	`FRE`	`@0 Eremomycine @4 INC @5 86`
C07	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Virose`
C07	`05`	`X`	`ENG`	`@0 Viral disease`
C07	`05`	`X`	`SPA`	`@0 Virosis`
C07	`06`	`X`	`FRE`	`@0 Infection`
C07	`06`	`X`	`ENG`	`@0 Infection`
C07	`06`	`X`	`SPA`	`@0 Infección`
C07	`07`	`X`	`FRE`	`@0 Peptide @5 37`
C07	`07`	`X`	`ENG`	`@0 Peptides @5 37`
C07	`07`	`X`	`SPA`	`@0 Péptido @5 37`
C07	`08`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 38`
C07	`08`	`X`	`ENG`	`@0 Respiratory disease @5 38`
C07	`08`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 38`
C07	`09`	`X`	`FRE`	`@0 Poumon pathologie @5 39`
C07	`09`	`X`	`ENG`	`@0 Lung disease @5 39`
C07	`09`	`X`	`SPA`	`@0 Pulmón patología @5 39`
C07	`10`	`X`	`FRE`	`@0 Polypeptide @5 41`
C07	`10`	`X`	`ENG`	`@0 Polypeptide @5 41`
C07	`10`	`X`	`SPA`	`@0 Polipéptido @5 41`
N21				`@1 317`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000452

Links to Exploration step

Pascal:06-0491667

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics</title>
<author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute of Virology, Faculty of Veterinary Medicine, University of Utrecht</s1>
<s2>Utrecht</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Printsevskaya, Svetlana S" sort="Printsevskaya, Svetlana S" uniqKey="Printsevskaya S" first="Svetlana S." last="Printsevskaya">Svetlana S. Printsevskaya</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Russie</country>
</affiliation>
</author>
<author><name sortKey="Olsufyeva, Eugenia N" sort="Olsufyeva, Eugenia N" uniqKey="Olsufyeva E" first="Eugenia N." last="Olsufyeva">Eugenia N. Olsufyeva</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Russie</country>
</affiliation>
</author>
<author><name sortKey="Solovieva, Svetlana E" sort="Solovieva, Svetlana E" uniqKey="Solovieva S" first="Svetlana E." last="Solovieva">Svetlana E. Solovieva</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Russie</country>
</affiliation>
</author>
<author><name sortKey="Preobrazhenskaya, Maria N" sort="Preobrazhenskaya, Maria N" uniqKey="Preobrazhenskaya M" first="Maria N." last="Preobrazhenskaya">Maria N. Preobrazhenskaya</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Russie</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0491667</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0491667 INIST</idno>
<idno type="RBID">Pascal:06-0491667</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000452</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000538</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics</title>
<author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute of Virology, Faculty of Veterinary Medicine, University of Utrecht</s1>
<s2>Utrecht</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Printsevskaya, Svetlana S" sort="Printsevskaya, Svetlana S" uniqKey="Printsevskaya S" first="Svetlana S." last="Printsevskaya">Svetlana S. Printsevskaya</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Russie</country>
</affiliation>
</author>
<author><name sortKey="Olsufyeva, Eugenia N" sort="Olsufyeva, Eugenia N" uniqKey="Olsufyeva E" first="Eugenia N." last="Olsufyeva">Eugenia N. Olsufyeva</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Russie</country>
</affiliation>
</author>
<author><name sortKey="Solovieva, Svetlana E" sort="Solovieva, Svetlana E" uniqKey="Solovieva S" first="Svetlana E." last="Solovieva">Svetlana E. Solovieva</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Russie</country>
</affiliation>
</author>
<author><name sortKey="Preobrazhenskaya, Maria N" sort="Preobrazhenskaya, Maria N" uniqKey="Preobrazhenskaya M" first="Maria N." last="Preobrazhenskaya">Maria N. Preobrazhenskaya</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Russie</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibiotic</term>
<term>Antiviral</term>
<term>Feline infectious peritonitis virus</term>
<term>Glycopeptide</term>
<term>Human</term>
<term>Research and development</term>
<term>Severe acute respiratory syndrome</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Structure activity relation</term>
<term>Teicoplanin</term>
<term>Vancomycin</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Homme</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Glycopeptide</term>
<term>Antibiotique</term>
<term>Antiviral</term>
<term>Relation structure activité</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Vancomycine</term>
<term>Teïcoplanine</term>
<term>Virus péritonite infectieuse féline</term>
<term>Recherche développement</term>
<term>Eremomycine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Antibiotique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC<sub>50</sub>
) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC<sub>50</sub>
 values of the glycopeptide derivatives for FIPV or SARS-CoV.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0166-3542</s0>
</fA01>
<fA02 i1="01"><s0>ARSRDR</s0>
</fA02>
<fA03 i2="1"><s0>Antivir. res.</s0>
</fA03>
<fA05><s2>72</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BALZARINI (Jan)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KEYAERTS (Els)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>VIJGEN (Leen)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>EGBERINK (Herman)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>DE CLERCQ (Erik)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>VAN RANST (Marc)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>PRINTSEVSKAYA (Svetlana S.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>OLSUFYEVA (Eugenia N.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>SOLOVIEVA (Svetlana E.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>PREOBRAZHENSKAYA (Maria N.)</s1>
</fA11>
<fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute of Virology, Faculty of Veterinary Medicine, University of Utrecht</s1>
<s2>Utrecht</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>20-33</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18839</s2>
<s5>354000142223690030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.1/2</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0491667</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Antiviral research</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC<sub>50</sub>
) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC<sub>50</sub>
 values of the glycopeptide derivatives for FIPV or SARS-CoV.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Homme</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Human</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Glycopeptide</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Glycopeptide</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Glicopéptido</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antibiotique</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antibiotic</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antibiótico</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Relation structure activité</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Structure activity relation</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Relación estructura actividad</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Vancomycine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Vancomycin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Vancomicina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Teïcoplanine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Teicoplanin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Teicoplanina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Virus péritonite infectieuse féline</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Feline infectious peritonitis virus</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Feline infectious peritonitis virus</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Recherche développement</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Research and development</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Investigación desarrollo</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Eremomycine</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Peptide</s0>
<s5>37</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Peptides</s0>
<s5>37</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Péptido</s0>
<s5>37</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Polypeptide</s0>
<s5>41</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Polypeptide</s0>
<s5>41</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Polipéptido</s0>
<s5>41</s5>
</fC07>
<fN21><s1>317</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000538 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000538 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:06-0491667
   |texte=   Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri